Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 3.09
NEPT's Cash to Debt is ranked higher than
68% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: 16.07 vs. NEPT: 3.09 )
NEPT' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 3.09

Equity to Asset 0.57
NEPT's Equity to Asset is ranked higher than
68% of the 772 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. NEPT: 0.57 )
NEPT' s 10-Year Equity to Asset Range
Min: -0.42   Max: 0.83
Current: 0.57

-0.42
0.83
F-Score: 3
Z-Score: 0.55
M-Score: -4.78
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -235.10
NEPT's Operating margin (%) is ranked higher than
63% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: -55.17 vs. NEPT: -235.10 )
NEPT' s 10-Year Operating margin (%) Range
Min: -116.18   Max: -9.17
Current: -235.1

-116.18
-9.17
Net-margin (%) -180.96
NEPT's Net-margin (%) is ranked higher than
65% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: -51.98 vs. NEPT: -180.96 )
NEPT' s 10-Year Net-margin (%) Range
Min: -156.23   Max: -10.08
Current: -180.96

-156.23
-10.08
ROE (%) -45.54
NEPT's ROE (%) is ranked higher than
66% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: -25.77 vs. NEPT: -45.54 )
NEPT' s 10-Year ROE (%) Range
Min: -596.63   Max: -9.66
Current: -45.54

-596.63
-9.66
ROA (%) -27.16
NEPT's ROA (%) is ranked higher than
70% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: -19.98 vs. NEPT: -27.16 )
NEPT' s 10-Year ROA (%) Range
Min: -82.24   Max: -5.71
Current: -27.16

-82.24
-5.71
ROC (Joel Greenblatt) (%) -68.68
NEPT's ROC (Joel Greenblatt) (%) is ranked higher than
77% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: -210.62 vs. NEPT: -68.68 )
NEPT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1925.98   Max: -12.44
Current: -68.68

-1925.98
-12.44
Revenue Growth (%) -7.90
NEPT's Revenue Growth (%) is ranked higher than
71% of the 653 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. NEPT: -7.90 )
NEPT' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 32
Current: -7.9

0
32
EBITDA Growth (%) 230.20
NEPT's EBITDA Growth (%) is ranked higher than
100% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. NEPT: 230.20 )
NEPT' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 230.2
Current: 230.2

0
230.2
EPS Growth (%) 89.00
NEPT's EPS Growth (%) is ranked higher than
99% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. NEPT: 89.00 )
NEPT' s 10-Year EPS Growth (%) Range
Min: -47.7   Max: 97.9
Current: 89

-47.7
97.9
» NEPT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2012

NEPT Guru Trades in Q3 2012

Steven Cohen 12,967 sh (New)
» More
Q4 2012

NEPT Guru Trades in Q4 2012

Steven Cohen Sold Out
» More
Q1 2014

NEPT Guru Trades in Q1 2014

Jim Simons 20,200 sh (New)
» More
Q2 2014

NEPT Guru Trades in Q2 2014

Jim Simons 40,900 sh (+102.48%)
» More
» Details

Insider Trades

Latest Guru Trades with NEPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.00
NEPT's P/B is ranked higher than
86% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 5.50 vs. NEPT: 2.00 )
NEPT' s 10-Year P/B Range
Min: 1.94   Max: 48
Current: 2

1.94
48
P/S 7.80
NEPT's P/S is ranked higher than
78% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 19.61 vs. NEPT: 7.80 )
NEPT' s 10-Year P/S Range
Min: 0.91   Max: 33.87
Current: 7.8

0.91
33.87
Current Ratio 4.79
NEPT's Current Ratio is ranked higher than
77% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. NEPT: 4.79 )
NEPT' s 10-Year Current Ratio Range
Min: 0.4   Max: 5.93
Current: 4.79

0.4
5.93
Quick Ratio 3.54
NEPT's Quick Ratio is ranked higher than
73% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 3.82 vs. NEPT: 3.54 )
NEPT' s 10-Year Quick Ratio Range
Min: 0.2   Max: 4.87
Current: 3.54

0.2
4.87

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 16.36
NEPT's Price/Net Current Asset Value is ranked higher than
79% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 57.00 vs. NEPT: 16.36 )
NEPT' s 10-Year Price/Net Current Asset Value Range
Min: 4.81   Max: 444
Current: 16.36

4.81
444
Price/Tangible Book 2.05
NEPT's Price/Tangible Book is ranked higher than
93% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 8.79 vs. NEPT: 2.05 )
NEPT' s 10-Year Price/Tangible Book Range
Min: 2.38   Max: 40.71
Current: 2.05

2.38
40.71
Price/Median PS Value 1.09
NEPT's Price/Median PS Value is ranked higher than
82% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. NEPT: 1.09 )
NEPT' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 9
Current: 1.09

0.12
9
Forward Rate of Return (Yacktman) -5.09
NEPT's Forward Rate of Return (Yacktman) is ranked higher than
79% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: -9.72 vs. NEPT: -5.09 )
NEPT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -5.4   Max: -2
Current: -5.09

-5.4
-2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NTB.Canada, NTU.Germany
Neptune Technologies & Bioressources Inc. was incorporated on October 9, 1998. It is a biotechnology company engaged in the development, manufacture and commercialization of marine‐derived omega‐3 polyunsaturated fatty acids. It is engaged in the research, development and commercialization of products derived from marine biomasses for the nutraceutical and pharmaceutical industries. The Company produces omega‐3 PUFAs through its patented process of extracting oils from Antartic krill, which omega‐3 PUFAs are then sold as bulk oil to company's distributors who commercialize them under their private label in the U.S., European and Australian nutraceutical markets. Its lead products, include Neptune Krill Oil (NKO) and ECOKRILL Oil (EKOTM), generally come in capsule form and serve as a dietary supplement to consumers. The Company has three reportable segments structured in three distinctive legal entities: the first is producing and commercializing nutraceutical products (Neptune), the second is the development and commercialization of pharmaceutical products for cardiovascular diseases applications (Acasti) and the third is the development and commercialization of pharmaceutical products for neurological diseases applications (NeuroBioPharm).
» More Articles for NAS:NEPT

Headlines

Articles On GuruFocus.com
What Drives St. Jude Medical to Be More Diversified? Apr 30 2014 

More From Other Websites
Neptune and BlueOcean Sign Licensing Agreement Oct 20 2014
Neptune and BlueOcean Sign Licensing Agreement Oct 20 2014
Acasti Announces Grant of Stock Options Oct 20 2014
Neptune Announces Normal Course Issuer Bid Oct 16 2014
Neptune Announces Second Quarter Results – Shipments of NKO® Underway Oct 16 2014
Neptune to Hold Conference Call to Discuss Second Quarter Results Oct 16 2014
Neptune Announces Normal Course Issuer Bid Oct 15 2014
Acasti Announces Second Quarter Results Oct 14 2014
Neptune Announces Second Quarter Results Oct 14 2014
Neptune to Hold Conference Call to Discuss Second Quarter Results Oct 08 2014
Acasti Announces Positive Top-Line Pharmacokinetic Results Sep 30 2014
Acasti Reports Successful CaPre(R) Phase II TRIFECTA Results Proving Statistically Significant... Sep 29 2014
Neptune Reaches Annualized Production Capacity of 100 Metric Tons Sep 23 2014
Short-term bulls diving for Neptune Sep 16 2014
Neptune to Present at Rodman & Renshaw Global Investment Conference Sep 03 2014
Neptune's Production Ramp-Up on Target Aug 14 2014
Why Neptune Technologies (NEPT) Could Be Positioned for a Slump Jul 30 2014
Has Enzymotec Been Over-Punished? Jun 09 2014
NEPTUNE TECHNOLOGIES & BIORESSOURCES INC. Financials Jun 06 2014
Neptune, Acasti and NeuroBioPharm Announce Litigation Regarding its Former Chief Executive Officer May 30 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK